The place of estramustine treatment in the treatment of prostate cancer;Az estramustin helye a prostatarák kezelésében

Orvosi Hetilap

Volumn 146, Issue 12, 2005, Pages 553-557

  Pintér, Oliver ^a,h   Tóth, Csaba ^b   Szabó, Zoltán ^c   Lipták, József ^c   Fél, Pál ^c   Papp, György ^d   Holman, Endre ^e   Hazay, Lajos ^c   Streit, Béla ^c   Kisbenedek, László ^f   Fehér, Miklós ^g   Kocsis, István ^c  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c Urológiai Osztály ^*  (Hungary)

^d Orszagos Gyogyintezeti Kozpont   (Hungary)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f Jahn Ferenc Del Pesti korhaz Budapest   (Hungary)

^g Miskolc Megyei Jogu Varos Onkormanyzata Semmeiweis Korhaz Rendelointezet   (Hungary)

^h UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Advanced prostate cancer; Estramustine; Prostate specific antigen

Indexed keywords

ESTRAMUSTINE; PROSTATE SPECIFIC ANTIGEN; ALKYLATING AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CLINICAL EVALUATION; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROSTATE TUMOR; SURVIVAL;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 19044372403     PISSN: 00306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Benson, R. C., Hartley-Asp, B.: Mechanisms of action and clinical uses of estramustine. Cancer Invest., 1990, 8, 375-380.
2. Bruchovsky, N., Rennie, P. S., Goldman, A. J. és mtsai: Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res., 1990, 50, 2275-2282.
3. Cantley, L. C., Neel, B. G.: New insights into tumor suppression PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA, 1999, 96, 4240-4245.
4. Craft, N., Chhor, C., Tran, C. és mtsai: Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res., 1999, 59, 5030-5036.
5. McDonnell, T. J., Troncoso, P., Brisbay, S. M. és mtsai: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res.,1992, 52, 6940-6944.
6. Eastham, J. A., Stapleton, A. M., Gousse, A. E. és mtsai: Association of p53 mutations with metastatic prostate cancer. Clin. Cancer Res., 1995, 1, 1111-1118.
7. Goldenberg, S. L. Bruchovsky, N., Rennie, P. S. és mtsa: The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma. J. Urol., 1988, 138, 1460-1465.
8. Hudes, G.: Estramustine-based chemotherapy. Semin Urol. Oncol., 1997, 15, 13-19.
9. Huggins, C., Hodges, C. V.: Studies on prostatic cancer, effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1941, 1, 293-297.
10. Isaacs, J. T., Coffey, D. S.: Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation as studied in the Dunning R-3327 H adenocarcinoma. Cancer Res., 1981, 41, 5070-5074.
11. Keller, E. T., Zhang, J., Cooper, C. R. és mtsai: Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metast. Rev., 2001, 20, 333-349.
12. Kreis, W.: Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer. Cancer Invest., 1995, 13, 296-312.
13. Labrie, F., Dupont, A., Belanger, A. és mtsai: New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen. J. Steroid Biochem., 1983, 19, 999-1007.
14. Murphy, G. P., Slack, N. H.: Response criteria for the prostate of the USA National Prostatic Cancer Project. Prostate, 1980, 1, 375-382.
15. Ottó, Sz.: Cancer epidemiology in Hungary and the Bela Johan National Program for the Decade of Health. Pathol. Oncol. Res., 2003, 9, 126-130.
16. Seidman, A. D., Scher, H. I., Petrylak, D. és mtsai: Estramustine and Vinblastine: use of prostate specific antigen as clinical trial end point for hormone refractory prostatic cancer. J. Urol., 1992, 147, 931-934.
17. Taplin, M. E., Bubley, G. J., Rajeshkumar, B. és mtsai: Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cance. Seminars Oncology, 2001, 28, 32-39.
18. Testa, J. R., Bellacosa, A.: AKT plays a central role in tumorgenesis Proc. Natl. Acad. Sci. USA, 2001, 98, 10983-10985.
19. Yagoda, A., Petrylak, D.: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer Supplement, 1993, 71, 1098-1109.
20. Veronesi, A., Lo Re, G., Foladore, S. és mtsai: Multidrug chemotherapy in the treatment of non-elderly patients with hormone-refractory prostatic carcinoma. Eur. Urol., 1996, 29, 434-438.
21. A second chance for prostate-cancer chemotherapy? The Lancet Oncology, 2003, 4, 13.